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Imperiale 2000). In addition, recombinant adenovirus (rAd) can transduce a wide variety of dividing and nondividing cell types, including neurons and glial cells (Davidson et al. 1993 ). rAd comes in three different "flavors": 1) first-generation vectors, which are deleted for the E1 and E3 genes and can package up to 8.2 kb of foreign DNA; 2) second-generation vectors, which have an improved safety profile compared with first-generation vectors through further deletion of the E2 or E4 genes and can package from 10 to 14 kb of foreign DNA; or 3) helper-dependent, "gutless" rAd vectors, which are completely devoid of any viral genes and can package up to 37 kb of foreign DNA (Danthinne and Imperiale 2000) . Moreover, there is a lack of long-term toxicity associated with first-and second-generation and helper-dependent adenoviruses used for intraparenchymal injections of doses up to but not higher than 1 ϫ 10 8 infectious units (IU) of recombinant virus (Lowenstein and Castro 2003; Lowenstein et al. 2007 ; Thomas et al. 2000 Thomas et al. , 2001 . Furthermore, Thomas et al. (2001) have shown that doses of 1 ϫ 10 7 IU/l of first-generation rAd lead to no cytotoxicity and no cell loss in the brain. This lack of toxicity combined with rAd's ability for stable transgene expression in the brain for up to a year make it an ideal vector for neuroscience applications (Gerdes et al. 2000; Lowenstein and Castro 2003; Palmer and Ng 2005) .
Many questions in neuroscience require high-level expression with rapid onset to understand the molecular mechanisms underpinning critical time periods of neuronal network development (Hanganu-Opatz 2010) . Furthermore, understanding basic mechanisms of synaptic transmission and plasticity requires high-level expression to perturb synaptic function in vivo, particularly with the use of dominant negatives (Young and Neher 2009) or channelrhodopsins (Lin 2011) . Although rAd is a double-stranded DNA virus and has a faster onset of expression compared with standard rAAV, due to rAAV's requirement for second-strand synthesis (Ferrari et al. 1996) , it still has been a challenge to develop neurospecific transgene expression cassettes that have rapid rates of onset and high levels of transgene expression. Despite the original successes of high-level transgene expression with the cytomegalovirus (CMV) promoter in rAd (Davidson et al. 1993; Gerdes et al. 2000; Smith et al. 2000) , due to the lack of neurospecificity (Kugler et al. 2001; Smith et al. 2000) and loss of transgene expression over time with the human cytomegalovirus (hCMV) promoter (Oral et al. 1997) , alternatives have been sought (Kugler et al. 2001 (Kugler et al. , 2003a . Previous studies have shown that the 2.2-kb neurospecific enolase (NSE) (Peel et al. 1997 ), 1.3-kb platelet-derived growth factor-␤ (PDGF) (Peel et al. 1997) , and 1.6-kb hybrid CMV-chicken ␤-actin (CAGGS) promoter drive neuronal expression (Klein et al. 2002; Niwa et al. 1991) , although their large size is a drawback when trying to package large cDNAs into either rAAV or rAd. Moreover, there is a lack of true neurorestrictiveness of the NSE promoter in a rAd background and the CAGGS promoter in general (Klein et al. 2002; Kugler et al. 2001 ). An attractive alternative to these promoters has been the 470-bp version of the human synapsin promoter (hSyn) (Kugler et al. 2001) . Despite the hSyn promoter being weaker compared with both the PDGF (Liu et al. 2006 ) and CMV promoters (Glover et al. 2002) , its small size and tight neurospecificity in vitro and in vivo in the context of rAAV (Kugler et al. 2003b) , rAd (Kugler et al. 2001) , and lentiviral vectors (LVV) (Gascon et al. 2008; Kuroda et al. 2008; Scott and Lois 2005) has led to its widespread use.
Given the need for a high-level neurospecific expression with early onset, the goal of this study was to create a novel high-level neurospecific expression construct for use in vitro and in vivo that would match the neurospecificity of the hSyn promoter but, unlike the hSyn promoter, lead to rapid onset and high levels of transgene expression. To create this expression cassette, we targeted every step that could lead to higher transgene expression from transcriptional, posttranscriptional, and posttranslational steps. To do so, we cloned previously reported cis-acting sequence elements that had been shown to increase the level of transgene expression into one transgene expression cassette to create pUNISHER. Our studies using enhanced green fluorescent protein (EGFP) as our reporter transgene demonstrate that the pUNISHER cassette led to a faster rate of onset of detectable transgene expression and higher level of transgene expression compared with a hSyn expression cassette in a rAd background. In addition, it was found that the Kv3.1 promoter and the Kv3.1 neurospecific enhancers (Gan et al. 1999; Gan et al. 1996) were not suitable cis elements for high-level transgene expression. In summary, based on the results of this study, a novel high-level neuronal expression cassette is available for multiple neuroscience applications.
MATERIAL AND METHODS
pUNISHER construction. The 470-bp hSyn promoter (Kugler et al. 2001 ) was provided by Dr. Sebastian Kugler (University of Göttin-gen). The Kv3.1 promoter was provided by Dr. Len Kaczmarek (Yale University), and the position from Ϫ266 to ϩ739 (Gan et al. 1996) was cloned. In addition, the 52-bp Kv3.1 enhancer from the Kv3.1 promoter was cloned (Gan et al. 1999) . The 5=-untranslated region of the amyloid precursor protein (5= APP UTR; Rogers et al. 1999 ) was synthesized: 5=-GTTAACGGTACCGGCCCCGGGAGACGGCGGCGG-TGGCGGCGCGGGCAGAGCAAGGACGCGGCGGATCCCACT-CGCACAGCAGCGCACTCGGTGCCCCGCGCAGGGTCGGTAC-CG-3=.
The minute virus of mice (MVM) intron sequence used was identical to the sequence used by Wu et al. (2008) . The bovine growth hormone polyadenylation signal (BGH polyA) sequence was cloned from pcDNA3.1Ϫ (Invitrogen). The tau 3= UTR was provided by Dr. Irith Ginzburg (Aronov et al. 1999) . The 592-bp woodchuck posttranscriptional regulatory element (WPRE) sequence used was identical to the sequence used by Hermening et al. (2006) . The hCMV enhancer used was identical to the one used by Hioki et al. (2007) and was cloned from pcDNA3.1. All elements were cloned into pDC511 (Microbix) to create pUNISHER.
Analysis of cis element effects on transgene expression levels. To determine the effects of the cis elements on transgene expression, we cloned the Renilla luciferase from pSiCheck (Promega) into the multiple cloning site (MCS) of pUNISHER. Firefly luciferase under the control of the thymidine kinase promoter was cloned into pDC511, and equimolar amounts of the various constructs with respect to each other were cotransfected into PC12 or 293 cells using Lipofectamine (Invitrogen). Firefly and Renilla luciferase levels were determined using a luminometer and the Dual-Luciferase assay protocol (Promega). Briefly, firefly levels were measured and then quenched, followed by measurement of Renilla luciferase levels. To normalize for differences in transfection efficiencies, transgene expression was plotted as Renilla signal divided by firefly signal. Transfections were done at minimum in triplicate. All data are means Ϯ SE. Either a t-test or ANOVA with Tukey's post hoc test was done to determine levels of significance at P Ͻ 0.05 or less.
Recombinant Ad production and titering. Second-generation rAd containing the E2a deletion were produced by cotransfecting the genomic helper plasmid (Microbix), which contained the E2a deletion (Zhou et al. 1996) , and the pUNISHER plasmid into E2T cells (Zhou and Beaudet 2000) . Subsequently, the standard protocols for rAd production were followed (Ng and Graham 2002) . rAd was stored at Ϫ80°C in storage buffer containing (in mM) 10 HEPES, 250 sucrose, and 1 MgCl 2 at pH 7.4 (Croyle et al. 1998) .
rAd PUN EGFP and rAd Syn EGFP were titered by limiting dilution. Briefly, E2T cells were seeded in a 96-well plate at a density of 5 ϫ 10 3 cells/well in 100 l of medium. Twenty-four hours later, the cells were washed twice with warmed Dulbecco's phosphatebuffered saline (DPBS) and incubated with 100 l of the virus dilution (10-and 2-fold dilutions of rAd PUN EGFP or rAd Syn EGFP) in triplicate. The cells were monitored daily for evidence of cytopathic effect. The titer of the adenoviral vectors, in plaqueforming units (pfu), was 2.05 ϫ 10 7 pfu/l for rAd PUN EGFP and 2.05 ϫ 10 7 pfu/l for rAd Syn EGFP. Primary culture of hippocampal neurons and astrocytes. Dissociated hippocampal cultures were prepared from postnatal day 0 to 1 (P0 -P1) Wistar rats using procedures previously described, with minor modification (Young 2005) . All animal use was approved by the Max Planck Florida Institute's Institutional Animal Care and Use Committee (IACUC). Briefly, rat hippocampi were removed under a dissection stereoscope and immersed in dissection solution containing (in mM) 125 NaCl, 3 KCl, 2 CaCl 2 , 1 MgCl 2 , 25 HEPES, 10 glucose, and 25 mannitol (pH 7.4, 315 mOsm). The hippocampi were then incubated in a papain (Worthington) solution (200 units) at 37°C for 20 min. Afterwards, the enzyme solution was removed and replaced with warmed Neurobasal-A medium (Invitrogen), supplemented with 2 mM GlutaMAX-I supplement (Invitrogen), 2% B-27 serum-free supplement (Invitrogen), penicillin (10 U/ml), and streptomycin (10 g/ml). The tissue was triturated, and cells were seeded in a 24-well plate at a density of 2 ϫ 10 4 cells/well. Twenty-four hours later, the medium was replaced.
The protocol used to isolate astrocytes was identical to that for hippocampal neurons, but the cells were first seeded in a T-75 flask. At 90% confluence, the cells were shaken overnight (200 rpm, 30°C) to remove all the remaining neurons and then washed twice with warmed medium. Subsequently, the astrocytes were trypsinized and plated in a 24-well plate at a density of 2 ϫ 10 4 cells/well. Cultures of both hippocampal neurons and astrocytes were maintained in an incubator at 37°C with 5% CO 2 .
Infection with adenoviral vectors and fluorescence analysis. Hippocampal neurons were infected at 7 days in vitro (DIV) with rAd PUN EGFP or rAd Syn EGFP at concentrations of 1 ϫ 10 3 and 1 ϫ 10 4 pfu/l and were imaged after 24, 48, and 120 h. Images were acquired using a DP21 digital camera (Olympus) mounted in a CKX41 inverted microscope (Olympus) equipped with a ϫ20 Olym-pus (LUC Plan FLN; NA 0.45) objective, an emission filter (520/35) for EGFP detection, and an X-Cite 120Q fluorescence illuminator (Lumen Dynamics, Mississauga, ON, Canada). The exposure time used for the acquisition of all the images was 50 ms, and the image resolution was 1,600 ϫ 1,200 pixels. The fluorescence intensity analysis at the soma of the neurons was done using Fiji software, after background subtraction, and is given as the average pixel value (ϮSE).
Astrocytes were infected with rAd PUN EGFP or rAd Syn EGFP adenoviral vectors using the same concentrations as for hippocampal neurons, 1 ϫ 10 3 and 1 ϫ 10 4 pfu/l, and imaged after 120h using the same parameters used for the primary hippocampal neurons.
Animal surgery. P1 Wistar rats were anesthetized with 95% O 2 mixed with 5% isoflurane using the CombiVet base system (Rothacher Medical, Bern, Switzerland) for 5 min. Afterwards, 50 l of 2% lidocaine solution were injected under the scalp and the animals were placed into a Kopf stereotactic frame (model 940 digital; David Kopf Instruments, Tujunga, CA). With the use of a gas mask (David Kopf Instruments), the animals were maintained under light anesthesia (0.5-0.8% isoflurane) using the CombiVet base system with humidifier. Animals were maintained at 37°C using an electronic thermometer linked to a heating pad (Harvard Apparatus, Holliston, MA).
The adenoviral vector was stereotactically injected into the ventral cochlear nucleus (VCN) at the brain stem. The injection coordinates were as follows (in mm): lambda relative to bregma, 0.2; anteriorposterior, 4.9; medial-lateral, 1.7; and dorsal-ventral, 5.7 . A final volume of 3 l (2 l of rAd Syn EGFP 1 ϫ 10 7 pfu/l or rAd PUN EGFP 1 ϫ 10 7 pfu/l stock mixed with 1 l of 20% mannitol in storage buffer) was injected using a calibrated injection capillary (Blaubrand; intraMARK, Wertheim, Germany) at a rate of 0.1 l/min. Once the solution was injected, the glass needle was kept in place for an additional 5 min to allow the dissipation of backpressure and was then slowly removed. The scalp was glued using Histocryl (B. Braun Melsungen, Melsungen, Germany). Animals were then placed under a heating lamp (Ϸ35°C), and after full recovery, animals were placed back in their respective cages. Animals were killed 4, 8, or 30 days later. This procedure and all surgical experiments were carried out under the strict guidelines of the Max Planck Florida Institute IACUC.
Fixation and slice preparation. After 4, 8, or 30 days, the animals were anesthetized by intraperitoneal injection with Avertin (250 mg/kg) and perfused transcardially with ice-cold DPBS until the flow became clear, followed by 100 ml of ice-cold DPBS containing 4% paraformaldehyde (PFA), pH 7.3, for 30 min at a flow rate of 2-3 ml/min. Afterwards, the brain was removed from the skull and postfixed in DPBS containing 4% PFA for 3-4 h. With the use of a Leica VT1200S vibratome (Leica Microsystems), 50-m slices of the brain stem, which included the medial nucleus of the trapezoid body (MNTB), were made in ice-cold solution containing (in mM) 125 NaCl, 2.5 KCl, 25 glucose, 25 NaHCO 3 , and 1.25 Na 2 PO 4 (pH 7.4, 310 mosM). Slices were then immunolabeled for neuron-specific nuclear protein (NeuN). Slices were permeabilized and blocked in 0.5% Triton X-100 (Sigma-Aldrich) in DPBS containing 4% fetal bovine serum (FBS; Thermo Fisher Scientific) for 2 h at room temperature (RT). The slices were incubated with primary antibody (1:500, mouse anti-NeuN, catalog no. MAB377; Millipore) in DPBS containing 1% FBS overnight at RT. Secondary antibody (1:500, goat anti-mouse IgG Alexa Fluor 647; Invitrogen) was incubated at RT in DPBS containing 3% FBS and 0.3%Triton X-100 for 2-3 h. Slices were then washed and mounted on slides, embedded with Aqua Poly/Mount (Polyscience), and enclosed with a coverslip.
Image acquisition. Slices were imaged using a Leica TCS SP5 II confocal laser scanning microscope (Leica Microsystems) equipped with a ϫ20 Leica (HCPL APO ϫ20/0.7 IMM glycerol/oil) objective, using an image resolution of 1,024 ϫ 1,024 and a zoom factor of 2, which gives a pixel size of 0.360 ϫ 0.360 m 2 , from two different fluorescence channels. Mosaic scanning was used to acquire the whole brain section (see Fig. 8, C , E, and G) by overlapping the different tiles (1,024 ϫ 1,024 pixels/tile). The image stacks from the calyxes (see Fig. 8 , D, F, and H) were taken using an image resolution of 1,024 ϫ 1,024 and a zoom factor of 1.7, which gives an effective voxel size of 0.424 ϫ 0.424 ϫ 0.642 m 3 . The final images are maximum projections of stacks, generated using Fiji software. Laser excitation wavelengths were 458 nm (argon) for EGFP and 633 nm (helium-neon) for Alexa Fluor 647. The wavelength selection windows used were 500 -570 nm for EGFP and 650 -730 nm for Alexa Fluor 647.
Electrophysiology and analysis. Transverse brain stem slices (200 m thick) containing the MNTB were prepared from P8 -P10 rats that had been injected with rAd PUN EGFP at P1 or from age-matched control rats not transduced with virus, as previously described (Borst et al. 1995; Forsythe 1994) . Slices were immediately transferred to an incubation chamber (37°C) containing standard extracellular solution containing (in mM) 125 NaCl, 2.5 KCl, 2 CaCl 2 , 1 MgCl 2 , 25 glucose, 25 NaHCO 3 , 25 NaH 2 PO 4 , 0.4 L-ascorbic acid, 3 myo-inositol, and 2 Na-pyruvate (pH 7.3, 310 mosM). After 1 h of incubation, slices were transferred to a recording chamber containing the same saline solution at RT. During the presynaptic and postsynaptic recording, the extracellular solution was supplemented with 1 M tetrodotoxin (Alomone Labs, Jerusalem, IL), 10 mM tetraethylammonium (TEA; Sigma, Steinheim, Germany), 50 M D-2-amino-5-phosphonopentanoic acid (Tocris Biosciences, Bristol, UK), 100 M cyclothiazide (Tocris), and 2 mM ␥-D-glutamylglycine (Tocris) as previously described (Sakaba and Neher 2001b) .
To visualize the cell pairs, slices were imaged using a chargecoupled device camera (Till Imago VGA; TILL Photonics, Graefeling, Germany) through a ϫ60 water-immersion objective (Olympus ϫ60/0.90W LUMPlanFl) on an upright microscope (Axioskop; Zeiss, Jena, Germany). To identify the EGFP-positive calyxes, slices were illuminated with an excitation wavelength of 470 nm using a Polychrome II xenon bulb monochromator (TILL Photonics). The presynaptic and postsynaptic compartments of the synapse were simultaneously voltage-clamped to Ϫ80 mV using a HEKA EPC 9/2 amplifier controlled by Patchmaster software (HEKA, Lambrecht, Germany). Recordings were low-pass filtered (6 kHz) and sampled at 50 kHz (20-s interval). For pair recordings, the pipette solution contained (in mM) 130 -145 Cs-gluconate, 20 TEA-Cl, 10 HEPES, 5 Na-phosphocreatine, 4 MgATP, 0.3 NaGTP, and 5 (postsynaptic patch pipette ) or 0.5 EGTA (presynaptic patch pipette) (pH 7.25, mOsm 320). Presynaptic series resistance was typically 8 -20 M⍀ and was compensated electrically to 8 M⍀. Postsynaptic series resistance (3-10 M⍀) was compensated to 3 M⍀ by the amplifier online; the remaining resistance was further compensated off-line.
RESULTS

Comparisons of cis-acting sequences necessary for generation of a high-level expression cassette.
To develop a highlevel neuronal transgene expression system in conjunction with a viral vector platform for molecular manipulations for in vivo neuronal applications, we tested cis-acting sequences that have been shown to increase transgene expression in vitro. Previous reports had demonstrated that cis-acting sequences that enhanced posttranscriptional and translational steps were effective in increasing transgene expression from various promoters (Brun et al. 2003; Glover et al. 2002; Loeb et al. 1999; Wu et al. 2008; Xu et al. 2002) . Since it had been reported that the 470-bp hSyn maintains neurospecificity in vitro and in vivo in multiple viral vector platforms (Gascon et al. 2008; Kugler et al. 2003b; Kugler et al. 2001; Kuroda et al. 2008; Scott and Lois 2005) , the 470-bp hSyn promoter expression cassette was chosen as the benchmark to compare the potential effects on the addition of the cis-acting elements on transgene expression Innovative Methodology levels (Kugler et al. 2001) . To screen which cis-acting sequences were optimal for high-level expression, we employed a luciferase expression-based assay in which the Renilla luciferase cDNA was cloned into various transgene expression cassettes (Fig. 1) .
Previous reports have demonstrated that addition of the 5= APP UTR (Brun et al. 2003) , WPRE (Donello et al. 1998) , tau 3= UTR (Aronov et al. 1999) , BGH polyA (Goodwin and Rottman 1992), and MVM intron (Wu et al. 2008 ) cis elements can significantly increase expression in either a rAAV, rAd, or LVV context (Brun et al. 2003; Glover et al. 2002; Loeb et al. 1999; Wu et al. 2008; Xu et al. 2002) . Since the 5= APP UTR, WPRE, and tau 3= UTR could be combined to significantly increase transgene expression (Brun et al. 2003) , the first goal was to determine whether the combination of these multiple elements with the MVM intron and the BGH polyA in conjunction with the hSyn promoter would lead to a significant increase in transgene expression compared with the original hSyn construct (Kugler et al. 2001) . Since many of these elements are reported to be neurospecific elements (Brun et al. 2003) , PC12 cells, which are considered more neuronal-like, were used to screen these constructs. The results of the luciferase assay demonstrated that these elements led to a 3.4-fold increase of expression compared with the original hSyn construct ( Fig. 2A ). Thus we conclude that the MVM intron and BGH poly A cis elements can be used in combination with the 5= APP UTR, WPRE, and tau 3= UTR cis elements and are effective in enhancing transgene expression from the hSyn promoter.
Although the hSyn promoter is neurospecific in vitro and in vivo, it is approximately three to four times weaker than the hCMV promoter (Glover et al. 2002) and is not an ideal promoter for high-level expression. An earlier report demonstrated that a 1-kb Kv3.1 promoter fragment that contained 266 bp of the Kv3.1 promoter and 739 bp of the 5= UTR was ϳ50% as strong as the hCMV promoter and maintained neurospeci- ficity (Gan et al. 1996) . On the basis of these previous results, replacing the hSyn promoter with the Kv3.1 promoter should give an approximately twofold increase in expression compared with the hSyn promoter. To test whether the Kv3.1 promoter would be an ideal replacement for the hSyn promoter, we cloned the 1-kb fragment of the Kv3.1 promoter (Gan et al. 1996) into an expression cassette identical to the 3= SynPun Ren (Fig. 1) to determine whether it would lead to an increased transgene expression level. In our assay, we found that the Kv3.1 promoter was 2.7 times weaker in driving transgene expression than the original hSyn transgene cassette ( Fig. 2A) and 10 times weaker than the addition of the posttranscriptional and translation sequences (3= SynPun Ren). In addition, we conclude that the Kv3.1 promoter is not an ideal promoter for use with the additional posttranscriptional and translation sequences.
It is well known that the addition of an intron in a transgene expression cassette is critical for high-level expression of cDNA (Le Hir et al. 2003) . Furthermore, it has been shown that placement of the intron 5= or 3= relative to the cDNA can significantly improve transgene expression depending on the intron used . Thus it became important to test whether the placement of the MVM intron in our transgene expression cassette was in the ideal location. To test whether the MVM intron placement was optimal, the MVM intron was inserted 5= to the Renilla luciferase cDNA (5= SynPun Ren) and resultant luciferase expression was compared against the 3= placement of the MVM intron (3' SynPun Ren). Figure 2B demonstrates that placement of the intron 5= or 3= after the Renilla cDNA had no statistically significant difference compared with each other on Renilla expression levels, although placement of the intron 3= to the cDNA led to a slightly higher level of expression.
The hCMV enhancer but not the Kv3.1 enhancer fused to the synapsin promoter significantly enhances transgene expression. Because Kv3.1 promoter was not an ideal replacement and we wanted to maintain the relative compactness of the hSyn promoter compared with other neurospecific promoters, attempts were made to increase the strength of the hSyn promoter but still maintain its neurospecificity. Multiple reports have shown that fusing various enhancers from disparate promoters to other promoters can lead to increases in promoter strength compared with the original promoter (Gray et al. 2011; Hioki et al. 2007; Liu et al. 2006; Niwa et al. 1991 ). Thus we focused on testing whether the 52-bp neurospecific enhancer from the Kv3.1 (Gan et al. 1999) or 365-bp hCMV nonspecific enhancer could significantly increase expression from the synapsin promoter (Hioki et al. 2007) . To do so, we cloned the 365-bp hCMV enhancer or 52-bp Kv3.1 enhancer 5= to the 470-bp hSyn promoter. Figure 3A shows that the hCMV enhancer led to a 3.2-fold increase in transgene expression, similar to a previous report of the hCMV enhancer fused to the hSyn promoter (Hioki et al. 2007 ), whereas addition of the 52-bp Kv3.1 enhancer only led to a slight increase in transgene expression, although not statistically significant.
Since a slight increase in transgene expression was seen with one copy of the 52-bp Kv3.1 enhancer, it was hypothesized that concatenating multiple copies of the Kv3.1 enhancer could lead to increased transgene expression. To test this, either 2 or 4 copies of the 52-bp Kv3.1 enhancer were concatenated and then cloned 5= to the hSyn promoter (Fig. 1) . Results from Fig.   3B demonstrate that increasing the copy number of the Kv3.1 enhancer led to slight increases in transgene expression; however, these were not statistically significant and were no better than having 1 copy of the 52-bp Kv3.1 enhancer. On the basis of these results, we confirm that the hCMV enhancer fused to the hSyn promoter significantly increased transgene expression and conclude that the 52-bp Kv3.1 enhancer fused alone or in multiple copies to the hSyn promoter does not improve transgene expression.
Combining all the transcriptional, posttranscriptional, and posttranslational elements into one cassette leads to a multiplicative increase of transgene expression in 293 cells but not PC12 cells. Based on our results that the posttranscriptional and posttranslational elements and transcriptional elements led to significant increases over the original hSyn transgene expression cassette, it remained to be tested whether combination of all elements together would lead to further increases in transgene expression. To do so, the hybrid hSyn promoter (hCMV enhancer ϩ hSyn promoter) was cloned into the transgene expression cassette containing the posttranscriptional and translation elements to create the transgene expression cassette pUNISHER (Fig. 1) . Our expectation was that the combination of all elements should lead to a multiplicative effect and ϳ10-fold increase (3.4-fold increase from 3= SynPun Ren and 3.3-fold increase from hCMV enhancer ϩ hSyn promoter) in transgene expression. Based on the results from the PC12 cells, the combination of all the elements in pUN-ISHER Ren led to a further increase of Renilla expression of ϳ7.4 fold and was not multiplicative (Fig. 4A) .
Since there was only a slight synergistic effect increase of expression in the PC12 cells, it remained a distinct possibility that we had saturated the pathways with these cis elements for maximizing transgene expression in these cells. To test this possibility, we decided to test for synergistic effects in 293 cells, which also express many proteins found in neurons (Shaw et al. 2002) . In addition, using the 293 cells allowed us to test whether the addition of hCMV enhancer affected the neurospecificity of the hSyn promoter. Figure 4B demonstrates that pUNISHER cassette led to a 16-fold increase in expression compared with the hSyn expression cassette. This was a multiplicative effect, since there was a twofold increase in expression with addition of the hCMV enhancer and an eightfold increase expression with all of the posttranscriptional and translational elements (3= SynPun Ren) compared with the hSyn construct. Thus we can conclude that all these elements act synergistically to increase transgene expression depending on the cell type. Furthermore, addition of the hCMV enhancer leads to a loss of neurospecificity of the synapsin promoter in vitro.
Second-generation Ad vectors expressing EGFP under the control of the pUNISHER cassette lead to a faster onset of detectable expression and high-level expression in primary neurons.
To overcome cell line-specific artifacts and potential artifacts due to the plasmid context of cis-acting elements (Xu et al. 2001 (Xu et al. , 2002 , primary hippocampal neurons were transduced with second-generation rAd viruses that expressed EGFP under control of the pUNISHER (rAd PUN EGFP) or original hSyn cassette (rAd Syn EGFP) to determine whether transgene expression was improved in a viral vector context.
To make quantitative measurements to test whether pUNISHER cassette led to increases in the rate of onset of detectable and higher levels of EGFP expression in a viral vector context, primary hippocampal neurons were infected with two different vector doses, 1 ϫ 10 3 or 1 ϫ 10 4 pfu/l. Subsequently, EGFP expression levels were measured at 24, 48, and 120 h after infection. As shown in Fig. 5 , A and D, rAd PUN EGFP expression led to an earlier onset of detectable expression compared with the rAd Syn EGFP at both vector doses. This was very evident at the 48-h time point at the 1 ϫ 10 3 pfu/l dose, where rAd PUN EGFP expression was on average 17 times higher, and at the 24-h time point in the 1 ϫ 10 4 pfu/l dose, where expression was on average 14 times higher compared with rAd Syn EGFP (Fig. 5, B and E) . In fact, there was little to no expression from the rAd Syn EGFP vector, but significant expression from rAd PUN EGFP, at these time points (Fig. 5, A and D) . In addition, at every time point measured, rAd PUN EGFP led to higher overall levels of EGFP expression (Fig. 5, A, C, D, and F) , although the relative Fig. 4 . The combination of all transcriptional and posttranscriptional elements leads to a multiplicative expression effect in 293 cells but not in PC12 cells. In addition, the hCMV enhancer fused to hSyn leads to a change in neuronal specificity. A: bar graph of normalized ratio of Renilla luciferase expression divided by firefly luciferase expression 48 h after transfection into PC12 cells with either hSyn Ren or pUNISHER Ren. Data are means Ϯ SE (n ϭ 3): hSyn Ren, 1.000 Ϯ 0.01189; pUNISHER Ren, 7.409 Ϯ 0.5075. P Ͻ 0.0001, hSyn Ren vs. pUNISHER Ren (t-test). B: similar to A, except hCMV enh Ren, 3= SynPun Ren, or pUNISHER Ren was used in addition to hSyn Ren. Data are means Ϯ SE (n ϭ 3): hSyn Ren, 1.000 Ϯ 0.02346; hCMV enh Ren, 2.125 Ϯ 0.09315; 3= SynPun Ren, 7.956 Ϯ 0.6415; pUNISHER Ren, 16.50 Ϯ 1.005. P Ͻ 0.001, hSyn Ren vs. hCMV enh Ren (t-test). B and E: summary of the average ratios of the rAd PUN EGFP intensity signal divided by the rAd Syn EGFP intensity signal for each condition using 1 ϫ 10 3 (B) or 1 ϫ 10 4 pfu/l dose (E). C and F: sample images of infected neurons for each incubation time using 1 ϫ 10 3 (C) or 1 ϫ 10 4 pfu/l dose (F). Transmission light (left) and fluorescence signal images (right) are shown. Scale bars, 100 m; n ϭ 30 cells for each condition and respective controls. ratio level of expression between rAd PUN EGFP and rAd Syn EGFP was not as dramatic at the later time points compared with the earlier time points in both experiments with 1 ϫ 10 3 or 1 ϫ 10 4 pfu/l. In summary, these results demonstrate that the faster rate of onset of detectable EGFP expression and higher total levels of EGFP expression from the pUNISHER expression cassette are not due to plasmid or cell line artifacts.
rAd PUN EGFP is expressed in primary cultured astrocytes. Although the pUNISHER expression cassette in a rAd context led to successful transduction of primary cultured neurons, it was important to determine whether the pUNISHER transgene cassette maintained neurospecificity in vitro, similar to previous reports of the hSyn promoter in an rAd context (Kugler et al. 2001 (Kugler et al. , 2003a . Our earlier experiments from the 293 cell lines had shown that the addition of the hCMV enhancer to the hSyn promoter led to a loss of the synapsin promoter's neurorestrictiveness in a plasmid context. To determine the neurospecificity of pUNISHER cassette in a viral context, primary rat hippocampal astrocytes were cultured and then infected with either 1 ϫ 10 3 or 1 ϫ 10 4 pfu/l of either rAd PUN EGFP or rAd Syn EGFP, and EGFP intensity was measured 120 h after infection. Figure 6 shows that EGFP expression was undetectable at both concentrations of virus of infected rAd Syn EGFP primary cultured astrocytes. However, significant EGFP signal in the astrocytes infected with rAd PUN EGFP was detected. Figure 6 , A and B, demonstrates that rAd PUN EGFP expression in astrocytes followed a dose-dependent manner also, with an ϳ5-fold increase in EGFP expression in the 1 ϫ 10 4 pfu/l compared with 1 ϫ 10 3 pfu/l concentration. These results indicate that the pUNISHER cassette in a rAd context is not neurospecific in vitro.
pUNISHER
cassette leads to highly correlated neuronal expression in vivo and leads to early onset, efficient transduction, and long-term expression at the calyx of Held synapse.
Although rAd PUN EGFP did not maintain neurospecificity in vitro, it was important to determine its transduction specificity in vivo, because in vitro conditions are not indicative of an in vivo setting. Recently, Hioki et al. (2007) had shown that the hCMV enhancer fused to a slightly smaller version (401 vs. 470 bp), which was identical to 470-bp hSyn promoter but removed the last 65 nucleotides from the 3= end of the 470-bp hSyn promoter, maintained neurospecific expression in the context of a VSV-G pseudo-typed LVV. Moreover, previous results had shown that at the brain stem, VSV-G pseudo-typed LVVs transduced 60% neurons and 40% astrocytes, whereas rAd type 5 serotype vectors transduced 40% neurons and 60% astrocytes (Duale et al. 2005) . Based on the lack of astrocyte expression from the LVV carrying a similar hybrid Syn promoter in vivo (Hioki et al. 2007) , it became important to determine whether the results concerning neurospecificity of rAd PUN EGFP in vitro correlated to an in vivo setting. To test neurospecificity of the pUNISHER cassette, 1 ϫ 10 7 pfu/l of either rAd PUN EGFP or rAd Syn EGFP was stereotactically injected into the auditory brain stem of P1 rats. Subsequently, the transduction pattern of the respective viruses was measured at the principal cells of the MNTB.
To test for neurospecificity, we used the NeuN antibody, since NeuN is an accepted neurospecific marker. The MNTB was chosen because the NeuN antibody gave reliable staining in this structure. Since it was possible that neurospecificity could be lost over time, neurospecificity was measured at 3, 7, and 29 days postinjection. In sharp contrast to our previous Fig. 6 . pUNISHER is expressed in astrocytes in vitro. Cultures astrocytes were infected with 1 ϫ 10 3 or 1 ϫ 10 4 pfu/l doses of rAd PUN EGFP and rAd Syn EGFP and imaged after 120 h. The average pixel intensity was measured only at the soma of the astrocytes after background subtraction. A: graph showing the raw data pixel intensity from cultured astrocytes infected with 1 ϫ 10 3 and 1 ϫ 10 results, which showed that pUNISHER cassette lost its neurospecificity in vitro, pUNISHER was highly correlated with neuronal expression in vivo (Fig. 7) . Figure 7B demonstrates that the percentage of EGFP-positive cells that were also NeuN positive was virtually identical between rAd PUN EGFP and rAd Syn EGFP at every time point analyzed (P4, P8, and P30). Thus, on the basis of our results, we can conclude that pUNISHER cassette maintains neuronal expression for the duration of its expression in vivo. The calyx of Held synapse is a giant axiosomatic glutamatergic synapse located within the MNTB in the auditory brain stem (Fig. 8A) , which has been widely used as a model synapse to understand the basic mechanisms of synaptic transmission and plasticity (Schneggenburger and Forsythe 2006) . Previously, it has been shown that the VCN could be reproducibly targeted by stereotactic methods that allow for molecular manipulations (Wimmer et al. 2004 (Wimmer et al. , 2006 Young and Neher 2009 ) and successful perturbation of synaptic function of the calyx of Held synapse by delivery of dominant negatives (Young and Neher 2009 ). However, it remained unknown how soon and how long pUNISHER cassette-driven expression was detected and maintained at the calyx synapse. To determine the rate of onset of detectable expression and duration of expression at the calyx, 1 ϫ 10 7 pfu/l rAd PUN EGFP virus was injected into P1 rats targeting the VCN following the previous established method of Young and Neher (2009) . As early as 72 h after injection, EGFP expression was detected not only in the cochlear nucleus but also in other regions in the auditory brain stem close to the injection site. More importantly, EGFP signal was detected at the calyx synapse (Fig. 8, C and D) . Further- more, EGFP-positive calyxes were detected at P30, indicating that the pUNISHER expression cassette was long lasting at the cochlear nucleus, in addition to other regions in the auditory brain stem. Thus we can conclude that the pUNISHER expression cassette from an Ad5 vector leads to early onset of detectable expression that can be maintained for weeks in the auditory brainstem.
pUNISHER EGFP expression from second-generation rAd vectors does not alter synaptic transmission and plasticity at the calyx of Held synapse. Although the calyx of Held synapse was able to be successfully transduced, it was important to determine whether high-level EGFP expression driven by the pUNISHER cassette affected the electrophysiological properties of the synapse. Since the large size of the calyx synapse allows for the direct simultaneous recordings from the pre-and postsynaptic compartments of the synapse, we were able to quantitatively determine whether any of the electrophysiological parameters were affected. To do so, pre-and postsynaptic compartments were voltage-clamped to Ϫ80 mV and short action potential-like (AP-like) depolarizations were applied to the calyx while the ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated postsynaptic currents were measured. Figure 9 , A and C, demonstrates that the presynaptic calcium currents elicited by an AP-like depolarization were unchanged compared with uninfected animals, and there was no difference in the postsynaptic response. To determine whether there were any effects on the size of the readily releasable pool (RRP), we applied a long depolarization protocol to the calyx, which allows for determination of the physiologically relevant RRP (Sakaba and Neher 2001a) . Figure 9 , B and D, demonstrates that there was no difference in either the presynaptic calcium currents or postsynaptic currents. By deconvolving the excitatory postsynaptic current (EPSC) of the long depolarization response and then integrating the release rates, one gets an accurate measure of the RRP (Sakaba and Neher 2001b) . Using this deconvolution method, we found that RRP size was unchanged (Fig. 9E) . Finally, it is known that in 2 mM Ca 2ϩ , 1 mM Mg 2ϩ , the calyx synapse will rapidly depress at 100-Hz stimulation (Schneggenburger et al. 1999) . To test potential effects on synaptic plasticity by the pUNISHER EGFP expression cassette, we applied 20 AP-like depolarizations at 100-Hz frequency to the calyx terminal and measured the resultant EPSCs. There was no difference in the responses at 100 Hz due to expression of EGFP from rAd PUN EGFP or wild-type control (Fig. 9, F and G) . Hence, we can conclude that high-level EGFP expression from rAd PUN EGFP does not affect synaptic transmission or plasticity at the calyx of Held synapse.
DISCUSSION
The goal of our study was to generate a high-level neurospecific transgene expression cassette that could be used in vitro and in vivo. We focused on those cis elements that are considered neurospecific to create pUNISHER, which, in conjunction with second-generation rAd vectors, leads to highlevel neuronal expression in vivo.
Development of a high-level expression cassette. Previous results have shown that the 470-bp hSyn promoter maintains neurospecificity in vitro and in vivo, not only in rAd vectors (Kugler et al. 2001 (Kugler et al. , 2003a but in rAAV (Kugler et al. 2003b) and LVV (Gascon et al. 2008; Kuroda et al. 2008; Scott and Lois 2005) . Because of its small size and strict neurospecificity in multiple viral contexts, the hSyn promoter has been extensively used for neurospecific transgene expression. However, because of its relative weakness compared with hCMV, multiple studies have focused on finding alternate strong neuro- Fig. 9 . rAd PUN EGFP does not alter electrophysiological responses at the calyx of Held synapse. A and B: sample traces of presynaptic calcium current charge (top) and excitatory postsynaptic current (EPSC; bottom) by pair recording from P8 -P10 rats injected with rAd PUN EGFP or from age-matched control (wild type, WT) animals not injected with virus. Calyxes were stimulated with an action potential (AP)-like depolarization (1-ms square-wave pulse from Ϫ80 to ϩ40 mV; A) or with a 50-ms depolarization (2 ms from Ϫ80 to ϩ70 mV followed by a 50-ms square-wave pulse to 0 mV; B). C and D: summary graphs showing the EPSC amplitude (left) and presynaptic calcium current charge (right) stimulated by AP-like depolarization (n ϭ 13 WT, n ϭ 10 rAd PUN EGFP; C) and by 50-ms depolarization (n ϭ 13 WT, n ϭ 10 rAd PUN EGFP; D). E: summary graph shows the readily releasable vesicle pool (RRP) size by deconvolving the EPSC of the long depolarization response and subsequent integration (n ϭ 11 WT, n ϭ 8 rAd PUN EGFP). F: EPSC and calcium current recorded from calyxes by 20 AP-like depolarizations at 100 Hz. Sample traces are from WT (top) and rAd PUN EGFP (bottom). G: each individual trace was normalized with its first EPSC amplitude and then averaged in WT (black) and rAd PUN EGFP (green) (n ϭ 11 WT, n ϭ 8 rAd Pun EGFP). Data are means Ϯ SE for all experiments. specific promoters with variable success (Klein et al. 2002; Kugler et al. 2001; Liu et al. 2004 Liu et al. , 2006 Peel et al. 1997) . Although the 1-kb Kv3.1 promoter (Ϫ266 from transcriptional start to ϩ739 bp of UTR) was reported to be a high-level neurospecific promoter (Gan et al. 1996) , in the context of the posttranslational and transcriptional modifications this promoter was not effective at all (Fig. 2A) . From our results, it is unclear why this promoter performed poorly. The Kv3.1 promoter contains a 739-bp UTR that is critical for expression, so it is a distinct possibility that the poor performance of the Kv3.1 promoter is due to interference between the 5= UTR and the other cis posttranscriptional and translational elements within our expression cassette.
It is important to note that in both characterizations on the strength of the Kv3.1 and the hSyn promoters an intron was not used in their original transgene expression cassettes, although they were in disparate cell types (PC12 Kv3.1 vs. 293 hSyn) (Gan et al. 1996; Glover et al. 2002) . Because introns can either enhance or reduce expression based on the promoter context, it remains a possibility that the MVM intron itself or the fact that an intron was used with the Kv3.1 promoter was responsible for its poor performance. Second, in contrast to the previous studies, which showed that placing an intron 5= close to the transcription initiation site can lead to an approximate threefold increase of transgene expression compared with 3= placement , no enhancement was detected with 5= placement compared with 3= placement in the context of the 470-bp hSyn promoter (Fig. 2B ).
Contrary to a previous report that contained a small 52-bp enhancer from the Kv3.1 promoter could significantly increase the strength of a basal promoter, we found that fusing it to the hSyn promoter resulted in a slight increase in promoter strength. This slight increase was minor compared with the hCMV enhancer. Attempts to concatenate the enhancer to increase its effectiveness did not result in any significant improvement. One possibility for the ineffectiveness of the 52-bp enhancer in the context of the hSyn promoter is that it may be in a suboptimal orientation or position respective to the transcription initiation site, while the hCMV enhancer is. Taken as a whole, our results clearly stress that characterizations of promoters and other cis elements may be context dependent and not applicable to other transgene expression cassettes.
Using pUNISHER in rAd vectors in vitro vs. in vivo. Consistent with previous results (Kugler et al. 2001; 2003a) , the hSyn promoter maintained its neurospecificity in vitro (Fig. 5 ) and in vivo (Fig. 7) in a rAd context. However, the pUNISHER cassette maintained highly correlated neuronal expression in vivo (Fig. 7) . Results from Hioki et al. (2007) had demonstrated that fusing the hCMV enhancer to the hSyn promoter maintained similar specificity to the hSyn promoter in the neostriatum with an ϳ10 -20% loss of specificity in other regions in the brain in a VSV-G pseudo-typed lentivirus background. Since they did not test their construct in vitro for neurospecificity, it is difficult to know whether the loss of neurospecificity of pUNISHER cassette is due to the viral context (rAd5 vs. rLenti) or to the differences in a cell culture environment compared with an in vivo environment. Knowing that general enhancers from the SV40 virus (Thiel et al. 1991) or hCMV virus (Hioki et al. 2007 ) cause a loss of neurospecificity in cell lines, and knowing that LVV and rAd5 infect glial cells in vivo with almost equal efficiency (Duale et al. 2005) , it is likely the loss of neurospecificity is due to differences between the environment in cell culture and in vivo setting. Furthermore, highly correlated neuronal expression was maintained throughout the latest time points tested in this study, P30, and we can rule out the effects of low levels of transcription that eventually lead to accumulation of EGFP and breakthrough expression.
Although determining the mechanisms in the differences in transduction patterns in vitro vs. in vivo with pUNISHER in an rAd type 5 background is outside the scope of this study, it points to inherent differences between in vitro primary neuronal and glial cultures compared with an in vivo setting. It is possible that the neurorestrictive silencing elements (NRSE) (Kraner et al. 1992; Mori et al. 1992 ) are more effective in an in vivo setting and prevent the loss of neuronal specificity in vivo. Another possible reason could be due to potential differences in transduction efficiencies of neurons or glial cells in vitro compared with an in vivo environment. It is important to note that in our study, neurospecificity was only measured in the auditory brain stem, in particular the MNTB, and not in other brain regions. It is possible that pUNISHER cassette may be less neurorestrictive in other brain regions. Future studies need to be carried out.
A high-level neuronal expression cassette for use in longterm in vivo expression. Results from the auditory brain stem demonstrated that EGFP expression could be detected in the cochlear nucleus and at the calyx of Held synapse within 72 h of stereotactic injection using pUNISHER cassette in conjunction with a rAd vector (Fig. 8) . Although it is difficult to accurately correlate the rate of onset of detectable expression between cultured neurons and an in vivo setting, we expect that EGFP expression most likely would be detected at an earlier time point at the site of injection and at the calyx. It is important to note that the calyx of Held is located 3-4 mm from the soma of the globular bushy cells, so the ability to detect transgenes at the synapse will differ significantly from detection at the soma due to differences in transport times between various proteins (Daly and Ziff 1997; Wimmer et al. 2004) . However, based on the previous report by Young and Neher (Young and Neher 2009) , 7 days was sufficient time for expression of a dominant negative synaptic vesicle protein, synaptotagmin 2, to interfere with synaptic transmission at the calyx, whereas 5 days were sufficient for a dominant negative Kv2.2 protein to interfere with Kv2.2 function at the principal cells of the MNTB using the pUNISHER cassette (KoppScheinpflug 2010). However, it was not the focus of the studies for determining minimum times for these dominant negatives to exert their influence, so it is possible, depending on the protein targeted, that dominant negative effects could be effective at earlier time points.
The ability of the pUNISHER cassette in an rAd context to have a faster onset of high expression compared with the original hSyn transgene expression cassette will allow for studying functions of proteins at critical time periods in the creation of the functional architecture in the auditory, somatosensory, or visual sensory systems in vivo (Hanganu-Opatz 2010) . Furthermore, pUNISHER is ideal when high levels of expression are necessary to perturb synaptic function in vivo such as the effective use of dominant negative proteins or channelrhodopsins and its variants (Lin 2011) . Based on the results of Fig. 5 on the high-level expression with pUNISHER cassette compared with hSyn rAd, use of pUNISHER may lead to a lower effective dose of rAd needed for equivalent expression by a log fold with rAd type 5 or even lower with more neurotropic Ad serotypes (Kremer et al. 2000; Peltekian et al. 2002) . These lower of effective doses with the pUNISHER cassette would reduce any potential unknown artifacts introduced by the rAd5 capsid (Stilwell et al. 2003) or in conjunction with other viral vectors capsids such as AAV (Stilwell and Samulski 2004) . In addition, it would reduce the possibility of inflammation from the brain's immune response (Lowenstein et al. 2007; Thomas et al. 2001) .
In addition, the high-level expression by pUNISHER rAd will be an effective tool for expressing neuronal tracers such as wheat germ agglutinin (Yoshihara et al. 1999) or EGFP fused to the COOH-terminal fragment of tetanus toxin Maskos et al. 2002) for mapping neuronal circuits. In this case, connections maybe revealed that might not have been detected before due to the low expression of neuronal tracers. Furthermore, since rAd has the ability to undergo retrograde transport (Ghadge et al. 1995; Kuo et al. 1995; Peltekian et al. 2002) , connections between neurons may be revealed with the use of pUNISHER that had not been seen before due to the inefficiency of retrograde transport of rAds in combination with weak expression cassettes.
Previous results have shown that the hCMV promoter is shut down over time in certain cell types (Klein et al. 1998; McCown et al. 1996) , leading to concerns that high-level expression vectors can be downregulated over time or can lead to toxicity. In our experiments, we did not see any changes in the synaptic properties of the transduced calyxes of Held, which effectively rules out any toxic side effects of high-level EGFP expression by pUNISHER cassette or by the rAd capsid or vector genome (Fig. 9) . Furthermore, loss of EGFP expression was not seen after 30 days postinjection in the auditory brain stem. However, it should be pointed out that toxicity due to high-level expression can be related to the transgene expressed in either an in vitro or in vivo setting over time. Thus it is important to test effects for potential effects on synaptic properties or membrane conductances that are unrelated to the transgene overexpressed.
In addition, Gray et al. (2011) have shown that the hCMV enhancer fused to the CBA promoter did not lead to a loss of expression in a self-complementary adeno-associated virus (scAAV) context, whereas the hCMV promoter itself did. Thus it is likely that the enhancer alone is not responsible for promoter downregulation but for sequences within the core of the hCMV promoter. However, it is known that expression driven by the hSyn promoter in first-generation rAd vectors was lost overtime in the substantia nigra, although it was unknown whether this was due to the 470-bp synapsin promoter itself or the remaining viral DNA found in the firstgeneration vector (Kugler et al. 2003a) . Based on these previous results, it still remains possible that expression from the pUNISHER cassette could be downregulated or lost depending on which cell types are targeted or which viral vector is used.
Use of pUNISHER in other recombinant vectors. It is well known that neurospecificity can be regulated by the tropism of the viral capsid; thus it is likely that pUNISHER-driven expression can be used in conjunction with more neurotropic viral vectors than the rAd type 5 background in this study. Use of more neurotropic vectors might be a way to overcome the lack of neurospecificity of pUNISHER in vitro or further decrease the effective dose of a given viral vector for transduction in vivo with pUNISHER. In this case one could use pUNISHER in combination with canine Ads, which are characterized to be more neurotropic (Kremer et al. 2000) , rAds in which capsids have been modified to retarget the virus to neurons (Schneider et al. 2000) , or rAd serotypes more efficient in transducing primary neurons (Chillon et al. 1999 ). In addition, it can be used with traditional rAAV vectors, which can package up to 5 kb of DNA, and in conjunction with all the various rAAV serotypes that are more neurotropic than AAV type 2 (Wu et al. 2006) . However, pUNISHER is 2.184 kb, which restricts its use with scAAV, since the transgene expression cassette plus transgene is restricted to 2.2 kb to create a double-stranded scAAV (McCarty et al. 2001) . Furthermore, pUNISHER could be used in conjunction with HSV amplicon systems to take advantage of their excellent neurotropism and for experiments that exceed the 37-kb foreign DNA limit of gutless adenoviruses (Marconi et al. 2010) . It should be noted that pUNISHER contains an intron and will restrict its usage to DNA viral vectors and not RNA-based viral vectors such as LLVs (Cockrell and Kafri 2007) . However, it is likely that high-level expression with the intron removed from pUNISHER can still be achieved in a lentiviral background.
In summary, these studies have established a transgene expression cassette that can be used for high-level neurospecific expression in vivo. We conclude that pUNISHER cassette in the context of rAd with numerous serotypes and other viral vectors will have a broad application for use in studying neuronal cell biology and manipulation of neuronal circuits in vivo.
